1
|
Lebon D, Dujardin A, Caulier A, Joris M, Charbonnier A, Gruson B, Quint M, Castelain S, François C, Lacassagne MN, Guillaume N, Marolleau JP, Morel P. Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease. Leuk Res 2023; 125:107005. [PMID: 36580876 DOI: 10.1016/j.leukres.2022.107005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Revised: 11/17/2022] [Accepted: 12/21/2022] [Indexed: 12/25/2022]
Abstract
OBJECTIVES Steroid-refractory graft-versus-host disease (SR-GVHD) is a challenging complication of allogeneic hematopoietic stem cell transplantation, and leads to high morbidity and mortality rates. The orally administered, selective Janus-associated kinase 1/2 inhibitor ruxolitinib gives overall response rates (ORR) of more than 70 % in acute and chronic SR-GVHD. However, several studies have highlighted an elevated risk of cytomegalovirus (CMV) reactivation in patients with ruxolitinib-treated SR-GVHD. METHODS We therefore analyzed risk of CMV and Epstein-Barr virus (EBV) primary infection or reactivation in 57 patients with ruxolitinib-treated GVHD, while taking account of the competing risk (CR) of death prior to the first reactivation. RESULTS Initiation of ruxolitinib treatment was a significant adverse prognostic factor for the CR of first CMV reactivation (hazard ratio (HR)= 1.747, 95 % confidence interval (CI): 1.33-2.92, p < 0.0001) and first EBV reactivation (HR=2.657, 95 % CI: 1.82-3.87, p < 0.0001) during GVHD. In our cohort of ruxolitinib-treated patients, the ORR (48 % and 58 % for acute and chronic GVHD, respectively) and the toxicity profile (haematological adverse events in 29.8 % of the patients) were similar to the literature values. CONCLUSION Given ruxolitinib's efficacy in SR-GVHD, use of this drug should not be limited by the fear of viral reactivation; however, our present results emphasize the importance of monitoring the viral load.
Collapse
Affiliation(s)
- Delphine Lebon
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens, Amiens, France; EA 4666, HEMATIM, Université de Picardie Jules Verne, Amiens, France.
| | - Adèle Dujardin
- Unité de Pharmacie Clinique Oncologique, CHU Amiens, Amiens, France
| | - Alexis Caulier
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens, Amiens, France; EA 4666, HEMATIM, Université de Picardie Jules Verne, Amiens, France
| | - Magalie Joris
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens, Amiens, France
| | - Amandine Charbonnier
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens, Amiens, France
| | - Bérengère Gruson
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens, Amiens, France
| | - Marine Quint
- Service de Recherche Clinique, CHU Amiens, Amiens, France
| | - Sandrine Castelain
- Laboratoire de Virologie, CHU Amiens, Amiens, France; UR 4294, UCVF, Université de Picardie Jules Verne, Amiens, France
| | - Catherine François
- Laboratoire de Virologie, CHU Amiens, Amiens, France; UR 4294, UCVF, Université de Picardie Jules Verne, Amiens, France
| | | | - Nicolas Guillaume
- EA 4666, HEMATIM, Université de Picardie Jules Verne, Amiens, France; Laboratoire d'Histocompatibilité, CHU Amiens, Amiens, France
| | - Jean-Pierre Marolleau
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens, Amiens, France; EA 4666, HEMATIM, Université de Picardie Jules Verne, Amiens, France
| | - Pierre Morel
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens, Amiens, France; Département de Biostatistiques, EA 2694-Santé publique, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille, France
| |
Collapse
|
2
|
Desoutter J, Ossart C, Lacassagne MN, Regnier A, Marolleau JP, Harrivel V. Cryopreservation and thawing of hematopoietic stem cell CD34-induced apoptosis through caspase pathway activation: Key role of granulocytes. Cytotherapy 2019; 21:612-618. [PMID: 31056424 DOI: 10.1016/j.jcyt.2019.04.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Revised: 02/26/2019] [Accepted: 04/08/2019] [Indexed: 10/26/2022]
Abstract
INTRODUCTION Cell damage inescapably occurs during both the freezing and the thawing graft processes for autologous hematopoietic stem cell (HSC) transplantation. To estimate HSC injury, a quality control is performed including: (i) CD34+ quantification; (ii) percentage of CD34+ viability and (iii) evaluation of HSC functional ability to form colony forming unit-granulocyte macrophage (CFU-GM). Apoptosis involves complex pathways such as caspase enzymes. Here, we assess the extent of apoptosis that is caspase-dependent before and after cryoconservation of CD34+, using a Fluorescent Labeled Inhibitor of CAspases (FLICA). METHODS Caspase pathway activation status was evaluated in 46 patients (multiple myeloma [n = 24], lymphoma [n = 22]), by flow cytometry, using a 7-aminoactinomycin-D (7AAD)/FLICA staining test, in CD34+, CD3+, CD14+ and CD56+ cells. Viable 7AAD-/FLICA+ cells were then correlated with various parameters. RESULTS We showed a significant caspase pathway activation, with 23% CD34+/7AAD-/FLICA+ cells after thawing, compared with the 2% described in fresh CD34+ cells (P < 0.0001). Moreover, caspase pathway was significantly activated in thawing CD3+, CD56+ and CD14+ cells. We also report a significant correlation between the rate of CD34+/7AAD-/FLICA+ cells and post-thawing granulocytes count (P = 0.042) and their potential to be differentiated into CFU-GM (P = 0.004). DISCUSSION Our results show substantial cell death, induced by the increase of caspase pathway activation, secondary to the thawing process, and across all study cell types. This observation may affect the immune response quality during recipient aplasia, without detecting a clinical impact. Moreover, caspase pathway activation through CD3+ and CD56+ subpopulations could modify the therapeutic result of donor lymphocytes infusion (DLI).
Collapse
Affiliation(s)
- Judith Desoutter
- Service d'Hématologie Biologique, Centre de Biologie Humaine, Centre Hospitalo-Universitaire Amiens Picardie, Amiens, France.
| | - Christele Ossart
- Laboratoire de Thérapie Cellulaire, Service d'Hématologie Clinique, Centre Hospitalo-Universitaire Amiens Picardie, Amiens, France
| | - Marie-Noëlle Lacassagne
- Laboratoire de Thérapie Cellulaire, Service d'Hématologie Clinique, Centre Hospitalo-Universitaire Amiens Picardie, Amiens, France
| | - Aline Regnier
- Laboratoire de Thérapie Cellulaire, Service d'Hématologie Clinique, Centre Hospitalo-Universitaire Amiens Picardie, Amiens, France
| | - Jean Pierre Marolleau
- Laboratoire de Thérapie Cellulaire, Service d'Hématologie Clinique, Centre Hospitalo-Universitaire Amiens Picardie, Amiens, France
| | - Veronique Harrivel
- Service d'Hématologie Biologique, Centre de Biologie Humaine, Centre Hospitalo-Universitaire Amiens Picardie, Amiens, France
| |
Collapse
|
3
|
De Vos J, Baudoux E, Bay JO, Calmels B, Cras A, El Cheikh J, Guerout-Verite MA, Lacassagne MN, Lamure S, Letellier C, Menard AL, Daguindau E, Poiré X, Yakoub-Agha I, Guillaume T. [Donor Lymphocyte Infusions (DLI): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2018; 106:S35-S39. [PMID: 30580911 DOI: 10.1016/j.bulcan.2018.10.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Accepted: 10/09/2018] [Indexed: 01/22/2023]
Abstract
Donor lymphocyte infusion (DLI) can be proposed to treat or prevent the relapse of malignant hemopathies following allogeneic stem cell transplantation. The efficiency has been mainly reported in the treatment of CML and low-grade lymphomas while the anti-tumoral activity is less in forms of acute leukemia and myelodysplastic syndromes. The GVL benefit should always be compared to the possible toxic effects of GVHD. This article updates the initial SFGM-TC recommendations, proposed in 2013, that were focused on the use of DLI. Doses of DLI in the context of haplo-identical stem cell transplantation are now indicated. We confirm that remaining mobilized stem cells may be used as classical DLI. The definition and the place of preemptive and prophylactic DLI are precisely given. Recommendations regarding the quality of thawed DLI as well as necessary clinical and biological follow-up are also described in detail.
Collapse
Affiliation(s)
- John De Vos
- Université Montpellier, CHU de Montpellier, unité de thérapie cellulaire, 80, avenue Augustin-Fliche, 34295 Montpellier, France.
| | - Etienne Baudoux
- Laboratoire de thérapie cellulaire, CHU de Liège, CHU B35 niveau-4E, Liège, Belgique
| | - Jacques-Olivier Bay
- CHU de Clermont-Ferrand, service de thérapie cellulaire et d'hématologie clinique adulte, site Estaing, 1, place Lucie-Aubrac, 63000 Clermont-Ferrand, France
| | - Boris Calmels
- Institut Paoli-Calmettes, centre de thérapie cellulaire, 232, boulevard Sainte-Marguerite, BP 156, 13273 Marseille cédex 09, France
| | - Audrey Cras
- Hôpital Saint-Louisn, CIC-BT, unité de thérapie cellulaire, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - Jean El Cheikh
- Hematology-Oncology Division, Naef K. Basile Cancer Institute-NKBCI, American University of Beirut Medical Center, 11-0236 Riad El Solh, 11072020 Beyrouth, Liban
| | | | - Marie-Noëlle Lacassagne
- CHU d'Amiens-Picardie, laboratoire de thérapie cellulaire, D408 route de Rouen, 80054 Amiens cédex 01, France
| | - Sylvain Lamure
- Hôpital Saint-Éloi, CHU de Montpellier, département d'hématologie clinique, 80, avenue Augustin-Fliche, 34295 Montpellier, France
| | - Catherine Letellier
- EFS Aquitaine-Limousin, service d'ingénierie cellulaire et tissulaire, CS21010, place Amelie Raba-Leon, 33075 Bordeaux cédex, France
| | - Anne-Lise Menard
- Centre Henri-Becquerel, département d'hématologie clinique, rue d'Amiens, 76038 Rouen, France
| | - Etienne Daguindau
- CHU de Besançon, département d'hématologie, 3, boulevard A. Fleming, 25030 Besançon, France
| | - Xavier Poiré
- Service d'hématologie, cliniques universitaires Saint-Luc, 10, avenue Hippocrate, Bruxelles, Belgique
| | - Ibrahim Yakoub-Agha
- CHRU de Lille, service des maladies du sang, 2, avenue Oscar-Lambret, 59037 Lille cédex, France; Université de Lille 2, LIRIC, Inserm U995, 59000 Lille, France
| | - Thierry Guillaume
- CHU de Nantes, Hôtel-Dieu, service d'hématologie, 1, place Ricordeau, 44000 Nantes, France.
| |
Collapse
|
4
|
Boulanger F, Decot V, Bulliard G, Calmels B, Giraud C, Lacassagne MN, Magnani A, Pouthier F, Thibert JB, Tirefort Y, Yakoub-Agha I, Baudoux E. Modalités de préparation, cryopréservation, décongélation des cellules souches hématopoïétiques et précautions pour infusion au patient : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull Cancer 2016; 103:S267-S272. [DOI: 10.1016/j.bulcan.2016.09.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Accepted: 09/01/2016] [Indexed: 11/29/2022]
|
5
|
Lecourt S, Marolleau JP, Fromigué O, Vauchez K, Andriamanalijaona R, Ternaux B, Lacassagne MN, Robert I, Boumédiene K, Chéreau F, Marie P, Larghéro J, Fiszman M, Vilquin JT. Characterization of distinct mesenchymal-like cell populations from human skeletal muscle in situ and in vitro. Exp Cell Res 2010; 316:2513-26. [PMID: 20430024 DOI: 10.1016/j.yexcr.2010.04.020] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2010] [Revised: 04/14/2010] [Accepted: 04/17/2010] [Indexed: 12/25/2022]
Abstract
Human skeletal muscle is an essential source of various cellular progenitors with potential therapeutic perspectives. We first used extracellular markers to identify in situ the main cell types located in a satellite position or in the endomysium of the skeletal muscle. Immunohistology revealed labeling of cells by markers of mesenchymal (CD13, CD29, CD44, CD47, CD49, CD62, CD73, CD90, CD105, CD146, and CD15 in this study), myogenic (CD56), angiogenic (CD31, CD34, CD106, CD146), hematopoietic (CD10, CD15, CD34) lineages. We then analysed cell phenotypes and fates in short- and long-term cultures of dissociated muscle biopsies in a proliferation medium favouring the expansion of myogenic cells. While CD56(+) cells grew rapidly, a population of CD15(+) cells emerged, partly from CD56(+) cells, and became individualized. Both populations expressed mesenchymal markers similar to that harboured by human bone marrow-derived mesenchymal stem cells. In differentiation media, both CD56(+) and CD15(+) cells shared osteogenic and chondrogenic abilities, while CD56(+) cells presented a myogenic capacity and CD15(+) cells presented an adipogenic capacity. An important proportion of cells expressed the CD34 antigen in situ and immediately after muscle dissociation. However, CD34 antigen did not persist in culture and this initial population gave rise to adipogenic cells. These results underline the diversity of human muscle cells, and the shared or restricted commitment abilities of the main lineages under defined conditions.
Collapse
Affiliation(s)
- Séverine Lecourt
- UPMC/AIM UMR S 974, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Terme M, Masurier C, Fernandez N, Lacassagne MN, Marolleau JP, Zitvogel L. [Role of dendritic cells in the modulation of innate effectors of immunity]. Pathol Biol (Paris) 2001; 49:475-7. [PMID: 11484608 DOI: 10.1016/s0369-8114(01)00170-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
CD8+ cytotoxic T lymphocytes (CTL), specifically directed against tumor-associated antigens, can be used in immunotherapy as effector cells in order to induce antitumor immune response. However, natural killer (NK) cells, that belong to the innate immune system, might also play a role on the anti-tumoral immune response. Our data show that quiescent NK cells can be activated by direct cell contact with dendritic cells (CD). Such a NK cells activating ability places DC at the frontier between innate and cognate immunity and then may encourage their use in clinical trials designed to elicit both CTL and NK responses.
Collapse
|